Retatrutide Half-Life: How Long It Stays in Your System (~6 Days)

Retatrutide (LY3437943) is an investigational triple agonist that activates the GLP-1, GIP, and glucagon receptors. One of the most common questions we get from research customers is deceptively simple: why is it dosed once a week? The answer is almost entirely pharmacokinetic — it comes down to how the molecule was engineered and what its plasma half-life looks like in published Phase 1 and Phase 2 data.

This is a plain-English walkthrough of the pharmacokinetics that set retatrutide's dosing cadence, written for research and educational purposes. It reports what the clinical literature describes; it is not medical advice, and the compound is not approved for human use.

What "half-life" actually means

A drug's elimination half-life is the time it takes for plasma concentration to fall by half once absorption is complete. It is the single number that most directly governs how often a compound has to be administered. For peptide therapeutics, three factors dominate that number:

• Proteolytic stability — how resistant the peptide backbone is to enzymes like DPP-4, which degrade native GLP-1 within minutes.
• Renal filtration — small peptides are filtered out by the kidneys quickly unless they are large enough, or bound tightly enough, to escape it.
• Albumin binding — many modern GLP-1-class analogs carry a fatty-acid side chain that reversibly binds serum albumin, which dramatically slows clearance by effectively hiding the peptide in a large carrier protein.

Retatrutide uses all three strategies at once. The native incretin sequence is modified at the positions DPP-4 typically attacks, and a C20 fatty-diacid linker tethers the peptide to albumin in circulation. That combination is the whole reason a molecule derived from a minutes-long hormone can be given weekly.

The reported numbers

Phase 1 single-ascending-dose work in healthy participants reported a mean terminal half-life of roughly six days for retatrutide. ^[2] Phase 1b and Phase 2 data in adults with type 2 diabetes and obesity were consistent with that figure, which is what supported the once-weekly subcutaneous schedule used across the clinical program.

For scale: native GLP-1 has a half-life measured in minutes. The gap between "minutes" and "six days" is almost entirely an engineering story. Albumin binding plus backbone modification buy several orders of magnitude of circulating time without changing the underlying receptor pharmacology — the molecule still engages GLP-1, GIP, and glucagon receptors the same way; it simply survives in plasma far longer to do so.

What a ~6-day half-life means in practice

Half-life is an abstract number until you translate it into behavior over weeks. A few consequences follow directly from it, and each one matters when interpreting a research protocol.

Steady state takes about a month

With weekly dosing, plasma levels rise week over week before they plateau. The standard pharmacokinetic rule of thumb — a drug approaches steady state after roughly five half-lives — puts retatrutide's plateau at around four to five weeks. Endpoints measured before that window can understate the compound's effect, because the subject has not yet reached the exposure the dose is designed to deliver. This is one reason trial readouts are reported at 24 and 48 weeks rather than early.

Missed doses don't crash levels

Because the compound accumulates across prior weeks, a single skipped dose lowers exposure but does not return a subject to baseline. This is very different from a short-acting tool, where one missed dose means the drug is essentially gone. It also matters when interpreting washout periods in crossover designs: a "washout" for a 6-day-half-life compound needs to be several weeks long to be real.

Titration works because the drug builds up

The clinical program escalated the dose in steps rather than starting high. A long half-life is what makes that strategy coherent: each step's exposure layers onto the last, so the system adapts gradually. This dose-escalation approach is also the standard tolerability lever for GLP-1-class compounds, where gastrointestinal effects are dose- and exposure-dependent.

How the half-life stacks up against other GLP-1-class compounds

Retatrutide's ~6-day half-life is not unusual for the modern, albumin-anchored generation of these molecules — it is roughly in line with semaglutide and tirzepatide, and all three are once-weekly. What sets retatrutide apart is not its pharmacokinetics but its receptor coverage (the triple GLP-1/GIP/glucagon profile). The half-life is what they share; the mechanism is where retatrutide diverges.

If you want the mechanism side of that comparison — what each receptor actually contributes and why the glucagon arm is the interesting one — that is covered in our companion piece on how retatrutide's triple-agonist mechanism works.

Why the engineering matters more than the number

It is tempting to treat "6 days" as a trivia figure. It is better understood as the payoff of a specific design decision. The field spent years trying to make incretin hormones last long enough to be practical drugs; the fatty-diacid/albumin approach is what finally made once-weekly — and now, in trials of related molecules, once-monthly — dosing conceivable. Retatrutide is a clean example of that engineering: same receptors as the endogenous hormones, radically different residence time in the body.

That is also why half-life is the parameter that most directly explains why retatrutide "feels" different from short-acting GLP-1 research tools in the lab. It is not more potent per molecule at the receptor; it is present for far longer, which changes everything about how exposure builds and how a protocol has to be timed.

For research and educational purposes only. Not medical advice. Reported pharmacokinetic figures describe published clinical studies, not a dosing recommendation. Retatrutide is a research compound and is not approved for human use.